CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function
Duohui Jing(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Kristina Hölig(German Red Cross), Heinz Reichmann(Technische Universität Dresden), Rainer Ordemann, Gerhard Ehninger(University Hospital Carl Gustav Carus), Tjalf Ziemssen(University Hospital Carl Gustav Carus), Uta Oelschlaegel(University Hospital Carl Gustav Carus)
Cited by 56
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402